Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis

Leukemia

Volumn 23, Issue 12, 2009, Pages 2281-2289

  Stamatopoulos, B ^a   Meuleman, N ^a   De Bruyn, C ^a   Mineur, P ^b   Martiat, P ^a   Bron, D ^a   Lagneaux, L ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Hopital St Joseph   (Belgium)

Author keywords

chronic lymphocytic leukemia; microarray; valproic acid

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DNA MICROARRAY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METHODOLOGY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; VALPROIC ACID;

EID: 74049162482     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.176     Document Type: Article

References (48)

1. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854. (Pubitemid 29430400)
2. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775. (Pubitemid 36514707)
3. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 1991; 78: 1901-1914.
4. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764. (Pubitemid 40322252)
5. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
6. Lin TS. What is the optimal initial treatment for chronic lymphocytic leukemia? Oncology (Williston Park) 2007; 21: 1641-1649.
7. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006; 107: 916-924. (Pubitemid 44291139)
8. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404. (Pubitemid 46105932)
9. Morotti A, Cilloni D, Parvis G, Guerrasio A, Saglio G. Thalidomide-induced partial stable remission in a case of refractory progressive B cell chronic lymphoid leukemia. Leuk Res 2008; 32: 506-507. (Pubitemid 351295902)
10. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349. (Pubitemid 46623164)
11. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76: 935-938. (Pubitemid 27401947)
12. Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 2002; 8: 662-664. (Pubitemid 34742091)
13. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 2004; 24: 25-31.
14. Olsen CM, Meussen-Elholm ET, Roste LS, Tauboll E. Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol 2004; 213: 173-179. (Pubitemid 38213144)
15. Kamitani H, Taniura S, Watanabe K, Sakamoto M, Watanabe T, Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro Oncol 2002; 4: 95-101. (Pubitemid 34285063)
16. Cinatl Jr J, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 2002; 20: 97-106.
17. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004; 18: 1246-1251. (Pubitemid 39023135)
18. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P et al. HDAC inhibitors induce apoptosis in glucocorticoidresistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 2007; 39: 1500-1509. (Pubitemid 47031039)
19. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110: 943-954. (Pubitemid 47312858)
20. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007; 35: 1527-1537. (Pubitemid 47419135)
21. Bokelmann I, Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro-and antiapoptotic proteins. Mol Med 2008; 14: 20-27. (Pubitemid 351356882)
22. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 41-52.
23. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al. Phase 1/2 study of the combination of 5-aza-20-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.
24. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884-3891. (Pubitemid 47477265)
25. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25: 1979-1985. (Pubitemid 46972780)
26. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009; 100: 28-36.
27. Ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007; 21: 248-252. (Pubitemid 46158116)
28. Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S et al. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 2006; 106: 1188-1196.
29. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem 2007; 53: 1757-1766. (Pubitemid 47509668)
30. Heimann P, Devalck C, Debusscher C, Sariban E, Vamos E. Alveolar soft-part sarcoma: further evidence by FISH for the involvement of chromosome band 17q25. Genes Chromosomes Cancer 1998; 23: 194-197. (Pubitemid 28402347)
31. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 1992; 29: 193-203.
32. Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005; 66: 52-61. (Pubitemid 40868919)
33. Finzer P, Ventz R, Kuntzen C, Seibert N, Soto U, Rosl F. Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. Virology 2002; 304: 265-273. (Pubitemid 36069168)
34. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846-855.
35. Chen J, Ghazawi FM, Bakkar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 2006; 5: 71.
36. Atmaca A, Al Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007; 97: 177-182. (Pubitemid 47057472)
37. Momparler RL. Cancer epigenetics. Oncogene 2003; 22: 6479-6483. (Pubitemid 37372327)
38. Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics 2004; 20: 3166-3178. (Pubitemid 39619206)
39. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206-222.
40. Aleskog A, Larsson R, Hoglund M, Kristensen J, Nygren P, Lindhagen E. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia. Anticancer Drugs 2005; 16: 277-283. (Pubitemid 40283942)
41. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762. (Pubitemid 34874007)
42. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D et al. Flavopiridol administered as a 24 h continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29: 1253-1257. (Pubitemid 41297636)
43. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 2519-2525.
44. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990; 82: 1133-1140. (Pubitemid 20213254)
45. Sonneveld P, Nooter K, Burghouts JT, Herweijer H, Adriaansen HJ, van Dongen JJ. High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496-1500.
46. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91: 248-251.
47. Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells. Leuk Res 2005; 29: 1335-1342. (Pubitemid 41297646)
48. Gil-Gomez G, Berns A, Brady HJ. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J 1998; 17: 7209-7218. (Pubitemid 29002690)